Primmune Therapeutics, Inc.
1 clinical trials · Sponsor
◉ Watch Primmune Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma (NCT07565285) | Primmune Therapeutics, Inc. | 2026-07-01 |
Track Primmune Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.